KPTI_OUT_1 [2025-04-02 15:45:52 -0400] 2190 Bytes | 648 tokens | Cum: 648 tkns (8.10% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Karyopharm Therapeutics (KPTI) hit my radar screen, up to 4.06 from a prev close of 3.54 Do you think its got more juice or is it lacking potential? It's 3:45:52 PM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Karyopharm Therapeutics (KPTI)
IPO: IPO date unknown
Shares Outstanding: 8,420,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Karyopharm Therapeutics:

C1 - Apr-01-25 04:05PM - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C2 - Apr-01-25 04:05PM 11:50AM - Biotech stocks slide as Marks resignation seen being negative for sector
C3 - Mar-03-25 04:05PM - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C4 - Feb-24-25 08:40AM - Karyopharm Announces 1-for-15 Reverse Stock Split
C5 - Feb-20-25 02:03AM - Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
C6 - Feb-20-25 02:03AM 01:39AM - Q4 2024 Karyopharm Therapeutics Inc Earnings Call
C7 - Feb-19-25 11:45AM - Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript
C8 - Feb-19-25 11:45AM 08:40AM - Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Karyopharm Therapeutics (KPTI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

KPTI_OUT_3 [2025-04-02 15:45:57 -0400] 1099 Bytes | 303 tokens | Cum: 953 tkns (11.91% of 8k)
==========================================================================

Showing C4 (chunk 1 of 10): C4:
**Karyopharm Announces 1-for-15 Reverse Stock Split**
Date: Feb-24-25 08:40AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/karyopharm-announces-1-for-15-reverse-stock-split-302383407.html

NEWTON, Mass.,Feb. 24, 2025/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at5:00 p.m. Eastern TimeonFebruary 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held onJanuary 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KPTI_OUT_5 [2025-04-02 15:45:57 -0400] 961 Bytes | 300 tokens | Cum: 1352 tkns (16.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T07:46:05Z - Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200-Day Moving Average - Here's What Hap...
A2 - 2025-03-18T15:52:39Z - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 23.7% in February...
A3 - 2025-03-18T13:37:12Z - KPTI stock touches 52-week low at $5.87 amid market challenges By Investing.com...
A4 - 2025-03-11T07:22:42Z - Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average - Time to Sell?...
A5 - 2025-03-06T07:43:16Z - RBC Capital Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KPTI_OUT_7 [2025-04-02 15:46:04 -0400] 1098 Bytes | 320 tokens | Cum: 1674 tkns (20.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200-Day Moving Average - Here's What Happened**Date: 2025-03-25Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/karyopharm-therapeutics-nasdaqkpti-stock-crosses-below-200-day-moving-average-heres-what-happened-2025-03-25/Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.65 and traded as low as $6.42. Karyopharm Therapeutics shares last traded at $6.51, with a volume of 45,358 shares changing hands.

Several equities research analysts have recently issued reports on KPTI shares. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KPTI_OUT_9 [2025-04-02 15:46:05 -0400] 891 Bytes | 308 tokens | Cum: 2117 tkns (26.46% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-01T13:45:00Z - International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
B2 - 2024-11-25T16:00:00Z - Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033
B3 - 2024-09-05T18:16:02Z - Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround
B4 - 2024-07-08T17:02:50Z - Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
B5 - 2024-05-08T20:45:10Z - Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
B6 - 2024-02-29T23:15:15Z - Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KPTI_OUT_11 [2025-04-02 15:46:09 -0400] 715 Bytes | 209 tokens | Cum: 2328 tkns (29.10% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/24/09/40732995/down-12-14-in-4-weeks-heres-why-karyopharm-therapeutics-looks-ripe-for-a-turnaroundKaryopharm Therapeutics (KPTI) has been beaten down lately, but the stock is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier, indicating a potential turnaround.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KPTI_OUT_13 [2025-04-02 15:46:10 -0400] 238 Bytes | 59 tokens | Cum: 2460 tkns (30.75% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KPTI_OUT_15 [2025-04-02 15:46:26 -0400] 8543 Bytes | 2329 tokens | Cum: 4791 tkns (59.89% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 77,487 | Perf Month: -37.68% | Option/Short: Yes / Yes | Sales Y/Y TTM: -0.55% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 107.90K | Perf Quarter: -62.20% | Short Float: 13.62% | ROE: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 0.77 | Index: - | Short Ratio: 9.91 | ROI: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 29.47 | Market Cap: 33.41M | Short Interest: 1.07M | Sales Surprise: -14.38% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.73 | Shs Outstand: 8.41M | Beta: 0.47 | EPS Surprise: 8.20% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -31.89% | Shs Float: 7.85M | Sales Q/Q: -9.50% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -49.18% | Inst Own: 48.33% | Sales past 5Y: 45.14% | Earnings: Feb 19 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -64.49% | Insider Own: 6.75% | Employees: 279 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -18.14% | Insider Trans: -8.09% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Mano Michael (SVP, General Counsel&Secretary) on 2025-03-04
- Common Stock: 2793 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Abate Kristin (Chief Accounting Officer) on 2025-03-04
- Common Stock: 571 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Poulton Stuart (EVP, Chief Development Officer) on 2025-03-04
- Common Stock: 3548 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Rangwala Reshma (EVP & Chief Medical Officer) on 2025-03-04
- Common Stock: 3587 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Paulson Richard A. (President and CEO) on 2025-03-04
- Common Stock: 11694 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Cheng Sohanya Roshan (EVP & Chief Commercial Officer) on 2025-03-04
- Common Stock: 3445 shares at $6.29 (D) Footnote: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Abate Kristin (Chief Accounting Officer) on 2025-02-28
- Common Stock: 933 shares at $0 (D)
- Stock Option (right to buy): 1866 shares at $0 (D)

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Poulton Stuart (EVP, Chief Development Officer) on 2025-02-28
- Common Stock: 5000 shares at $0 (D)
- Common Stock: 4583 shares at $0 (D)
- Stock Option (right to buy): 10000 shares at $0 (D)
- Stock Option (right to buy): 9166 shares at $0 (D)

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Rangwala Reshma (EVP & Chief Medical Officer) on 2025-02-28
- Common Stock: 5416 shares at $0 (D)
- Common Stock: 4583 shares at $0 (D)
- Stock Option (right to buy): 10833 shares at $0 (D)
- Stock Option (right to buy): 9166 shares at $0 (D)

Inside Trans: Karyopharm Therapeutics Inc. (KPTI) by Cheng Sohanya Roshan (EVP & Chief Commercial Officer) on 2025-02-28
- Common Stock: 5416 shares at $0 (D)
- Common Stock: 4583 shares at $0 (D)
- Stock Option (right to buy): 10833 shares at $0 (D)
- Stock Option (right to buy): 9166 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 148442000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -87479000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.04
Average Volume: 156677.13
30-Day High: 7.66
30-Day Low: 3.54

[Detailed Financials: Q3 2024]
- Total Assets: $189,476,000.0
- Total Liabilities: $349,123,000.0
- Total Equity: $-159,647,000.0
- Current Assets: $184,755,000.0
- Current Liabilities: $61,493,000.0

[Income Statement: Q3 2024]
- Revenue: $38,783,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.26

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-11,943,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $213,977,000.0
- Total Liabilities: $346,117,000.0
- Total Equity: $-132,140,000.0
- Current Assets: $208,540,000.0
- Current Liabilities: $57,619,000.0

[Income Statement: Q2 2024]
- Revenue: $42,786,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.15

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $31,902,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

KPTI_OUT_17 [2025-04-02 15:46:29 -0400] 676 Bytes | 167 tokens | Cum: 5272 tkns (65.90% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

KPTI_IN_19 [2025-04-02 15:46:29 -0400] 126 Bytes | 29 tokens | Cum: 5372 tkns (67.15% of 8k)
==========================================================================

====================================
[2025-04-02 15:46:29] # Analysis Completed
Elapsed Time: 37.57 seconds